Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer - Cohort study of XELOX in combination with bevacizumab for unresectable or recurrent colorectal cancer(KSCC0902)

Kyushu Study group of Clinical Cancer0 个研究点目标入组 41 人开始时间: 2010年7月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Co-mobility, such as infection, heart failure, history of cardiac infarction, liver cirrhosis, viral hepatitis type B , jaundice, kidney failure, uncontrolled hypertension, diabetes, interstitial lung disease, lung fibrosis, pulmonary emphysema. 2.Coelomic fluid which need therapy( pleural effusion, abdominal dropsy, pericardial fluid) 3.History of the severe hypersensitivity 4.Active other malignancies. 5.History of mental disorder, central nerve disorder, cerebral vascular disorder. 6.Brain metastasis 7.Evidence of bleeding diathesis, intestinal paralysis , ileus, peptic ulcer, traumatic bone fracture 8.Watery stools or Grade 2 or more diarrhea 9.Surgical procedure within 4 weeks before registration (implantation of the central venous port within 1 week before registration.) 10.Requiring anti-thrombogenic therapy to prevent thrombosis 11.Requiring immunosuppressive drug or steroid drug 12.Pregnant or lactating woman 13.Not appropriate for the study at the physician's assessment

发起方

Kyushu Study group of Clinical Cancer